<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17147808</article-id><article-id pub-id-type="pmc">1693922</article-id><article-id pub-id-type="publisher-id">1471-2407-6-274</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-274</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Sadighi</surname><given-names>Sanambar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ssadighi@doctor.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Mohagheghi</surname><given-names>Mohammad Ali</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mamohagheghi@yahoo.com</email></contrib><contrib id="A3" corresp="yes" contrib-type="author"><name><surname>Montazeri</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ali@jdcord.jd.ac.ir</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Sadighi</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sedighi_zahra@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Cancer Research Center, Cancer Institute, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="I2"><label>2</label>Iranian Institute for Health Sciences Research, Tehran, Iran</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2006</year></pub-date><volume>6</volume><fpage>274</fpage><lpage>274</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/274"></ext-link><history><date date-type="received"><day>17</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>Copyright Â© 2006 Sadighi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Sadighi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3209" xml_f="3219" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3230" xml_f="3484" txt_i="22" txt_f="276">Health related quality of life (HRQOL) is an important outcome after treatment for upper gastrointestinal carcinoma. This study aimed to compare HRQOL in patients with advanced gastric cancer (GC) receiving either a standard or an experimental treatment.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3525" xml_f="3532" txt_i="278" txt_f="285">Methods</offsets></title><p><offsets xml_i="3543" xml_f="3885" txt_i="286" txt_f="628">Seventy-one patients have been treated in Cancer Institute (Tehran, Iran) with docetaxel, cisplatin, 5 FU (TCF) or epirubicin, cisplatin, 5-FU (ECF) and were followed from Jan 2002 to Jan 2005. End points were response rate, HRQOL and survival. HRQOL was assessed using the EORCT QLQ-C30 at baseline and after the third cycle of chemotherapy.</offsets></p></sec><sec><title><offsets xml_i="3907" xml_f="3914" txt_i="630" txt_f="637">Results</offsets></title><p><offsets xml_i="3925" xml_f="4402" txt_i="638" txt_f="1115">The baseline HRQOL scores were comparable between two groups. After treatment improvement was seen in a number of items and domains except for cognitive functioning, and diarrhoea. Pain decreased and physical functioning improved in both groups. However, only the TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001). Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups.</offsets></p></sec><sec><title><offsets xml_i="4424" xml_f="4434" txt_i="1117" txt_f="1127">Conclusion</offsets></title><p><offsets xml_i="4445" xml_f="4724" txt_i="1128" txt_f="1407">Docetaxel based treatment (TCF) showed better palliation and improvement of global QOL as compared with epirubicin based treatment (ECF). However, it seems that regardless of treatment offered, effective chemotherapy was the most important factor affecting QOL in these patients.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="4786" xml_f="4796" txt_i="1416" txt_f="1426">Background</offsets></title><p><offsets xml_i="4807" xml_f="5310" txt_i="1427" txt_f="1930">When assessing the value of a particular anticancer treatment it is important to consider the impact it may have not only on length of survival but also on health related quality of life (HRQOL). In medical care of patients with gastric cancer, the 5-year survival is a crucial outcome. However, in the last few years there has been an increasing awareness about quality of survival. HRQOL especially is important for patients suffering from advanced gastric cancer, whose life expectancy may be short [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5341" xml_f="5342" txt_i="1930" txt_f="1931">1</offsets></xref><offsets xml_i="5349" xml_f="5715" txt_i="1931" txt_f="2297">]. Despite the fact that numerous comparative therapeutic studies have been completed, there are relatively few reports of comparisons of the HRQOL effects of these differing therapies. Given that most patients with advanced gastric cancer are not cured and many regimens have similar efficacy, differences in HRQOL may help to determine which regimen is preferred [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5746" xml_f="5747" txt_i="2297" txt_f="2298">2</offsets></xref><offsets xml_i="5754" xml_f="5972" txt_i="2298" txt_f="2516">]. As it has been suggested using quality of life assessment in clinical trials of patients with gastric cancer will help to define the role of potentially curative surgery, palliative treatments and adjuvant therapy [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6003" xml_f="6004" txt_i="2516" txt_f="2517">3</offsets></xref><offsets xml_i="6011" xml_f="6158" txt_i="2517" txt_f="2664">]. A recent study demonstrated that quality of life might improve in patients with advanced gastric cancer, treated with second-line chemotherapy [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6189" xml_f="6190" txt_i="2664" txt_f="2665">4</offsets></xref><offsets xml_i="6197" xml_f="6199" txt_i="2665" txt_f="2667">].</offsets></p><p><offsets xml_i="6206" xml_f="6478" txt_i="2668" txt_f="2940">This article reports the results of HRQOL assessments obtained at baseline and after 3 cycles of chemotherapy in Iranian patients with advanced gastric adenocarcinoma enrolled in a randomized clinical trial of docetaxel, cisplatin, 5-FU versus epirubicin, cisplatin, 5-FU.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="6519" xml_f="6526" txt_i="2942" txt_f="2949">Methods</offsets></title><sec><title><offsets xml_i="6546" xml_f="6552" txt_i="2950" txt_f="2956">Design</offsets></title><p><offsets xml_i="6563" xml_f="6827" txt_i="2957" txt_f="3221">Patients with histological confirmed gastric adenocarcinoma were entered into this randomized trial. Patients with primary or recurrent gastric adenocarcinoma (stage III or IV) were randomly assigned to receive three to six cycles of either ECF (epirubicin 60 mg/m</offsets><sup><offsets xml_i="6832" xml_f="6833" txt_i="3221" txt_f="3222">2</offsets></sup><offsets xml_i="6839" xml_f="6858" txt_i="3222" txt_f="3241">, cisplatin 60 mg/m</offsets><sup><offsets xml_i="6863" xml_f="6865" txt_i="3241" txt_f="3243">2 </offsets></sup><offsets xml_i="6871" xml_f="6888" txt_i="3243" txt_f="3260">and 5-FU 750 mg/m</offsets><sup><offsets xml_i="6893" xml_f="6894" txt_i="3260" txt_f="3261">2</offsets></sup><offsets xml_i="6900" xml_f="6961" txt_i="3261" txt_f="3322">/day as 5 days continuous infusion) or TCF (docetaxel 60 mg/m</offsets><sup><offsets xml_i="6966" xml_f="6967" txt_i="3322" txt_f="3323">2</offsets></sup><offsets xml_i="6973" xml_f="6992" txt_i="3323" txt_f="3342">, cisplatin 60 mg/m</offsets><sup><offsets xml_i="6997" xml_f="6999" txt_i="3342" txt_f="3344">2 </offsets></sup><offsets xml_i="7005" xml_f="7022" txt_i="3344" txt_f="3361">and 5-FU 750 mg/m</offsets><sup><offsets xml_i="7027" xml_f="7029" txt_i="3361" txt_f="3363">2 </offsets></sup><offsets xml_i="7035" xml_f="7153" txt_i="3363" txt_f="3481">in the same dose and schedule of ECF) every 3 weeks. There were no industry funding, fees or salary for this protocol.</offsets></p><p><offsets xml_i="7160" xml_f="7435" txt_i="3482" txt_f="3757">The primary objective of the study was to determine whether substitution of docetaxel for epirubicin in combination with cisplatin and 5-FU would improve response rate of advanced gastric cancer. Secondary endpoints were QOL, overall survival, and progression-free survival [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7466" xml_f="7467" txt_i="3757" txt_f="3758">5</offsets></xref><offsets xml_i="7474" xml_f="7663" txt_i="3758" txt_f="3947">]. The Cancer Research Center review board approved the study and all patients signed the written informed consent dictated by the ethics committee of Tehran University of Medical Sciences.</offsets></p></sec><sec><title><offsets xml_i="7685" xml_f="7711" txt_i="3949" txt_f="3975">Quality of life assessment</offsets></title><p><offsets xml_i="7722" xml_f="7877" txt_i="3976" txt_f="4131">QOL was assessed using the Iranian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QLQ-C30 [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7908" xml_f="7909" txt_i="4131" txt_f="4132">6</offsets></xref><offsets xml_i="7916" xml_f="8016" txt_i="4132" txt_f="4232">]. It is one of the best-known cancer-specific questionnaires for measuring QOL in cancer patients [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8047" xml_f="8048" txt_i="4232" txt_f="4233">7</offsets></xref><offsets xml_i="8055" xml_f="8532" txt_i="4233" txt_f="4710">]. The questionnaire is consisting of 30 items assessing five functional domains (physical, role, emotional cognitive, and social), symptom scales (fatigue, nausea and pain) and six single items (dyspnoea, sleep disturbances, appetite loss, constipation, diarrhoea, and financial impact of the disease and treatment), and a single global QOL scale. Quality of life was assessed before the first cycle of chemotherapy, and within one month after the third cycle of chemotherapy.</offsets></p></sec><sec><title><offsets xml_i="8554" xml_f="8574" txt_i="4712" txt_f="4732">Statistical analysis</offsets></title><p><offsets xml_i="8585" xml_f="8804" txt_i="4733" txt_f="4952">For comparing patients' characteristics in two groups t-test or chi-square were used. The QLQ-C30 responses were scored and analyzed according to the scoring manual provided by the EORTC Study Group on Quality of Life [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8835" xml_f="8836" txt_i="4952" txt_f="4953">8</offsets></xref><offsets xml_i="8843" xml_f="9206" txt_i="4953" txt_f="5316">]. First, the mean baseline scores for each treatment groups were calculated. Then, after treatment, the mean change score from baseline was calculated for all patients and compared between the two treatment groups. Two-related sample t-test (paired samples t-test) was used for statistical comparison. Survival analysis was performed using the Kaplan-Meier test.</offsets></p></sec></sec><sec><title><offsets xml_i="9234" xml_f="9241" txt_i="5319" txt_f="5326">Results</offsets></title><p><offsets xml_i="9252" xml_f="9633" txt_i="5327" txt_f="5708">Between January 2002 and January 2005, 86 patients were randomized into the two study groups. Objective response rate (more than 50% decreases in tumor size) was seen in 37% and 42% of ECF and TCF group respectively. Although surgery results were better in the TCF group (P = 0.01), we did not find statistically significant differences in clinical response to chemotherapy (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="9665" xml_f="9666" txt_i="5708" txt_f="5709">1</offsets></xref><offsets xml_i="9673" xml_f="9675" txt_i="5709" txt_f="5711">).</offsets></p><p><offsets xml_i="9682" xml_f="9858" txt_i="5712" txt_f="5888">For HRQOL evaluation, only 71 patients were included in the comparative analysis because 15 patients did not complete the QOL measurements at the beginning of the study. Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="9890" xml_f="9891" txt_i="5888" txt_f="5889">1</offsets></xref><offsets xml_i="9898" xml_f="10406" txt_i="5889" txt_f="6397"> shows demographic and clinical characteristics of the study sample, as well as the 71 participants in the QOL assessment by the treatment arms. They were quite similar. Most patients underwent a laparotomy before the study and had measurable residual or metastatic disease. The most frequent sites of disease at the time of random assignment were peritoneum, liver and paraaortic lymph nodes in both groups. Compliance with QOL questionnaire completion was excellent. Less than 4% of items had missing data.</offsets></p><p><offsets xml_i="10413" xml_f="10488" txt_i="6398" txt_f="6473">The baseline quality of life scores for each study arms are shown in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="10520" xml_f="10521" txt_i="6473" txt_f="6474">2</offsets></xref><offsets xml_i="10528" xml_f="10844" txt_i="6474" txt_f="6790">. At baseline and before chemotherapy patients in both groups showed impairment of global quality of life and most of functioning scales except for cognitive functioning. The baseline QOL scores were comparable between two groups, with the exception of emotional functioning and a better global QOL in the ECF group.</offsets></p><p><offsets xml_i="10851" xml_f="10857" txt_i="6791" txt_f="6797">Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="10889" xml_f="10890" txt_i="6797" txt_f="6798">3</offsets></xref><offsets xml_i="10897" xml_f="11510" txt_i="6798" txt_f="7411"> lists the mean score changes from baseline to post treatment by the two study arms. Generally both groups showed improvements compared with their baseline status in a number of domains and items except for cognitive functioning, diarrhoea and financial aspect of disease and treatment that showed deterioration. Although in both groups physical functioning improved and pain decreased but only in the TCF group statistically and clinically significant improvement was observed for global QOL (P = 0.001), social (P = 0.03) and emotional functioning (P = 0.004), pain (P = 0.03) and sleep difficulties (P = 0.02).</offsets></p><p><offsets xml_i="11517" xml_f="11636" txt_i="7412" txt_f="7531">To examine whether the observed differences were significant, comparisons were made and the results are shown in Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="11668" xml_f="11669" txt_i="7531" txt_f="7532">4</offsets></xref><offsets xml_i="11676" xml_f="11857" txt_i="7532" txt_f="7713">. As indicated there were no significant differences between two groups after treatment except for social functioning (P = 0.03) and nausea and vomiting (P = 0.01) in the TCF group.</offsets></p><p><offsets xml_i="11864" xml_f="12088" txt_i="7714" txt_f="7938">Patients with proven tumor regression most frequently had an improvement of HRQOL domains (by example the follow-up global quality of life scores for responding and not responding patients to chemotherapy is shown in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12118" xml_f="12119" txt_i="7938" txt_f="7939">1</offsets></xref><offsets xml_i="12126" xml_f="12293" txt_i="7939" txt_f="8106">. However, the median survival time for both groups was 12 months with a 95% confidence interval of 8 to 14 and 7 to 17 months for the ECF and TCF groups respectively.</offsets></p></sec><sec><title><offsets xml_i="12315" xml_f="12325" txt_i="8108" txt_f="8118">Discussion</offsets></title><p><offsets xml_i="12336" xml_f="12838" txt_i="8119" txt_f="8621">This trial was undertaken primarily to determine if TCF offered superior response rate compared with a standard ECF treatment. QOL measures were assessed to provide patient-reported symptoms, both disease and treatment related, as well as providing a general assessment of global well-being and functional status of patients treated with these chemotherapy regimens. The study demonstrated a better response with the TCF group (although not significant) and very similar survival between two regimens [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="12869" xml_f="12870" txt_i="8621" txt_f="8622">5</offsets></xref><offsets xml_i="12877" xml_f="12879" txt_i="8622" txt_f="8624">].</offsets></p><p><offsets xml_i="12886" xml_f="13067" txt_i="8625" txt_f="8806">Based on our data the TCF regimen was associated with a meaningful improvement in health related QOL. Although overall about 40% of the patients had major response to chemotherapy [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="13098" xml_f="13099" txt_i="8806" txt_f="8807">5</offsets></xref><offsets xml_i="13106" xml_f="13457" txt_i="8807" txt_f="9158">], the study findings suggest that improvement of HRQOL was due to palliative effect of chemotherapy. The lack of apparent impact of toxicity on global functioning of responding patients is clinically useful data that may assist both the patient and the physician in the discussion about the anticipated effects of the proposed chemotherapy treatment.</offsets></p><p><offsets xml_i="13464" xml_f="13775" txt_i="9159" txt_f="9470">The EORTC QLQ-C30 was sensitive to detect HRQOL issues that were important to patients within our specific treatment groups. To identify aspects of HRQOL in which the patients clearly had gained meaningful improvement, a significant change of 5 points and p value less than 0.03 was considered to be important [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="13806" xml_f="13807" txt_i="9470" txt_f="9471">9</offsets></xref><offsets xml_i="13814" xml_f="14071" txt_i="9471" txt_f="9728">]. Accordingly one might argue that patients in the TCF group experienced a better QOL after their treatments. For example the TCF group shoed 9.7 points change in their baseline global quality of life while the same figure for the ECF group was 2.4 points.</offsets></p><p><offsets xml_i="14078" xml_f="14939" txt_i="9729" txt_f="10590">As in any HRQOL analysis, the data need to be interpreted with caution bearing in mind the study limitations. This study represents QOL information for 71 patients (80% of patients who took part in the study), although their baseline characteristics were comparable with the entire patients. In addition, the baseline QOL scores and symptoms in some patients may have been due to the effect of surgery (laparotomy) rather than gastric cancer itself. Thus, improvement in QOL and symptoms may have occurred even in the absence of chemotherapy. However, one should consider that HRQOL improvement was confined only to the responders and were not seen in patients who experienced progression of the disease. There is evidence that the type of surgery does not significantly influence the quality of life in patients undergoing curative surgery for gastric cancer [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="14971" xml_f="14973" txt_i="10590" txt_f="10592">10</offsets></xref><offsets xml_i="14980" xml_f="14982" txt_i="10592" txt_f="10594">].</offsets></p><p><offsets xml_i="14989" xml_f="15563" txt_i="10595" txt_f="11169">Unfortunately at the time of current project the Iranian version of the FACT-G (a well known general cancer specific quality of life questionnaire) or EORTC QLQ-STO22, a site-specific measure of quality of life in patients with gastric cancer were not available to use in this study. Therefore it is important that in the future studies at least to supplement the QLQ-C30 with the QLQ-STO22 in measuring quality of life in patients with gastric cancer undergoing surgery, surgery and chemo-radiotherapy, palliative chemotherapy, palliative surgery and best supportive care [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="15595" xml_f="15597" txt_i="11169" txt_f="11171">11</offsets></xref><offsets xml_i="15604" xml_f="15763" txt_i="11171" txt_f="11330">]. As suggested QOL in patients with gastric cancer deserves more systematic studies, especially as one of the outcome measures in randomized clinical trials [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="15794" xml_f="15795" txt_i="11330" txt_f="11331">1</offsets></xref><offsets xml_i="15802" xml_f="15804" txt_i="11331" txt_f="11333">].</offsets></p></sec><sec><title><offsets xml_i="15826" xml_f="15836" txt_i="11335" txt_f="11345">Conclusion</offsets></title><p><offsets xml_i="15847" xml_f="16325" txt_i="11346" txt_f="11824">In conclusion, QOL measures provide helpful information of patient-reported symptoms that is essential for full evaluation of new treatments for patients with gastric cancer. The study findings indicated that the group treated with TCF enjoyed more improvement with regard to global QOL as compared with the group that treated with ECF. However, it seems that regardless of treatment offered, effective chemotherapy was the most important factor affecting QOL in these patients.</offsets></p></sec><sec><title><offsets xml_i="16347" xml_f="16366" txt_i="11826" txt_f="11845">Competing interests</offsets></title><p><offsets xml_i="16377" xml_f="16437" txt_i="11846" txt_f="11906">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="16459" xml_f="16481" txt_i="11908" txt_f="11930">Authors' contributions</offsets></title><p><offsets xml_i="16492" xml_f="16877" txt_i="11931" txt_f="12316">SS was the main investigator, designer and executive manager of the clinical trial. MAM participated in the design of the study and carried out all of the patients operations. AM participated in the design and acquisition of QOL data and performed the statistical analysis. ZS participated in the sequence alignment and coordination. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="16899" xml_f="16922" txt_i="12318" txt_f="12341">Pre-publication history</offsets></title><p><offsets xml_i="16933" xml_f="16997" txt_i="12342" txt_f="12406">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/274/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors wish to thank the personnel of the cancer research center specially Dr Mosavi Jarrahi and Dr Nahvigoo for their cooperation. The research deputy of Tehran University of Medical Sciences supported this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaptein</surname><given-names>AA</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>J</given-names></name></person-group><article-title>Quality of life in gastric cancer</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>3189</fpage><lpage>3196</lpage><pub-id pub-id-type="pmid">15929166</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blazeby</surname><given-names>JM</given-names></name><name><surname>Nicklin</surname><given-names>J</given-names></name><name><surname>Brookes</surname><given-names>ST</given-names></name><name><surname>Winstone</surname><given-names>K</given-names></name><name><surname>Alderson</surname><given-names>D</given-names></name></person-group><article-title>Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12888819</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6601146</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blazeby</surname><given-names>JM</given-names></name></person-group><article-title>The role of quality of life assessment in gastric cancer</article-title><source>Jpn J Clin Oncol</source><year>2000</year><volume>30</volume><fpage>246</fpage><pub-id pub-id-type="pmid">10857505</pub-id><pub-id pub-id-type="doi">10.1093/jjco/30.5.246</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Bang</surname><given-names>SM</given-names></name><name><surname>Cho</surname><given-names>EK</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name></person-group><article-title>Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>57</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">16010588</pub-id><pub-id pub-id-type="doi">10.1007/s00280-005-0055-y</pub-id></citation></ref><ref id="B5"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Sadighi</surname><given-names>S</given-names></name><name><surname>Mohagheghi</surname><given-names>MA</given-names></name><name><surname>Meemari</surname><given-names>F</given-names></name></person-group><article-title>Randomized clinical trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU in advanced gastric adenocarcinoma</article-title><source>J of Med Faculty of Tehran University of Medical Sciences</source><comment>[in Persian]</comment></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montazeri</surname><given-names>A</given-names></name><name><surname>Harirchi</surname><given-names>I</given-names></name><name><surname>Vahdani</surname><given-names>M</given-names></name><name><surname>Khaleghi</surname><given-names>F</given-names></name><name><surname>Jarvandi</surname><given-names>S</given-names></name><name><surname>Ebrahimi</surname><given-names>M</given-names></name><name><surname>Haji-Mahmoodi</surname><given-names>M</given-names></name></person-group><article-title>The EORTC QLQ-C30 translation and validation study of the Iranian version</article-title><source>Support Care Cancer</source><year>1999</year><volume>7</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">10541982</pub-id><pub-id pub-id-type="doi">10.1007/s005200050300</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><name><surname>Filiberti</surname><given-names>A</given-names></name><name><surname>Flechtner</surname><given-names>H</given-names></name><name><surname>Fleishman</surname><given-names>SB</given-names></name><name><surname>de Haes</surname><given-names>JC</given-names></name></person-group><article-title>The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology</article-title><source>J Nat Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">8433390</pub-id></citation></ref><ref id="B8"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fayers</surname><given-names>P</given-names></name><name><surname>Aarenson</surname><given-names>N</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name></person-group><source>EORTC QLQ-C30 Scoring Manual</source><year>2001</year><publisher-name>EORTC Quality of Life Group, Brussels, Belgium</publisher-name></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Rodrigues</surname><given-names>G</given-names></name><name><surname>Myles</surname><given-names>J</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Pater</surname><given-names>J</given-names></name></person-group><article-title>Interpreting the significance of changes in health-related quality of life scores</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">9440735</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz De Liano</surname><given-names>A</given-names></name><name><surname>Oteiza</surname><given-names>MF</given-names></name><name><surname>Ciga</surname><given-names>MA</given-names></name><name><surname>Aizcorbe</surname><given-names>M</given-names></name><name><surname>Cobo</surname><given-names>F</given-names></name><name><surname>Trujillo</surname><given-names>R</given-names></name></person-group><article-title>Impact of surgical procedure for gastric cancer on quality of life</article-title><source>Br J Surg</source><year>2003</year><volume>90</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">12520582</pub-id><pub-id pub-id-type="doi">10.1002/bjs.4011</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blazeby</surname><given-names>JM</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Vickery</surname><given-names>C</given-names></name><name><surname>Arraras</surname><given-names>J</given-names></name><name><surname>Sezer</surname><given-names>O</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Koller</surname><given-names>M</given-names></name><name><surname>Turhal</surname><given-names>NS</given-names></name><name><surname>Stuart</surname><given-names>R</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>D'haese</surname><given-names>S</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name></person-group><article-title>Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO22, to assess quality of life in patients with gastric cancer</article-title><source>Eur J Cancer</source><year>2004</year><volume>40</volume><fpage>2260</fpage><lpage>2268</lpage><pub-id pub-id-type="pmid">15454251</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2004.05.023</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Follow-up global quality of life scores in responding and not responding patients for each treatment group (Higher values show better global quality of life): ECF: Mean score (SD); Responding 63.5 (14.2), Not responding 54.2 (14.9). TCF: Mean score (SD); Responding 63.3 (16.6), Not responding 48.8 (13.5).</p></caption><graphic xlink:href="1471-2407-6-274-1"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The characteristics of patients in each treatment arms</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><bold>ECF group<sup>1</sup></bold></td><td align="left" colspan="2"><bold>TCF group<sup>2</sup></bold></td><td align="left"><bold>P<sup>4</sup></bold></td></tr></thead><tbody><tr><td></td><td align="left">All (n = 42) No. (%)</td><td align="left">QOL<sup>3 </sup>(n = 35) No. (%)</td><td align="left">All (n = 44) No. (%)</td><td align="left">QOL<sup>3 </sup>(n = 36) No. (%)</td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Age</bold></td><td></td><td></td><td></td><td></td><td align="left">0.23</td></tr><tr><td align="left">Mean (SD)</td><td align="left">57. 2 (9.83)</td><td align="left">58.1 (10.48)</td><td align="left">55.4 (14.04)</td><td align="left">54.2 (16.18)</td><td></td></tr><tr><td align="left"><bold>Gender</bold></td><td></td><td></td><td></td><td></td><td align="left">0.20</td></tr><tr><td align="left">Male</td><td align="left">34 (81)</td><td align="left">28 (80)</td><td align="left">31 (70)</td><td align="left">24 (67)</td><td></td></tr><tr><td align="left">Female</td><td align="left">8 (19)</td><td align="left">7 (20)</td><td align="left">13 (30)</td><td align="left">12 (33)</td><td></td></tr><tr><td align="left"><bold>Tumor size</bold></td><td></td><td></td><td></td><td></td><td align="left">0.48</td></tr><tr><td align="left">T2</td><td align="left">8 (19)</td><td align="left">8 (23)</td><td align="left">5 (11)</td><td align="left">5 (14)</td><td></td></tr><tr><td align="left">T3</td><td align="left">15 (36)</td><td align="left">12 (34)</td><td align="left">15 (34)</td><td align="left">11 (31)</td><td></td></tr><tr><td align="left">T4</td><td align="left">19 (45)</td><td align="left">15 (43)</td><td align="left">24 (55)</td><td align="left">20 (55)</td><td></td></tr><tr><td align="left"><bold>Lymph node</bold></td><td></td><td></td><td></td><td></td><td align="left">0.39</td></tr><tr><td align="left">L1</td><td align="left">20 (48)</td><td align="left">18 (51)</td><td align="left">14 (32)</td><td align="left">14 (39)</td><td></td></tr><tr><td align="left">L2</td><td align="left">17 (40)</td><td align="left">13 (37)</td><td align="left">20 (45)</td><td align="left">14 (39)</td><td></td></tr><tr><td align="left">Not involvement</td><td align="left">5 (12)</td><td align="left">4 (12)</td><td align="left">10 (23)</td><td align="left">8 (22)</td><td></td></tr><tr><td align="left"><bold>Differentiation</bold></td><td></td><td></td><td></td><td></td><td align="left">0.30</td></tr><tr><td align="left">Well differentiated</td><td align="left">7 (17)</td><td align="left">7 (20)</td><td align="left">5 (11)</td><td align="left">4 (11)</td><td></td></tr><tr><td align="left">Others</td><td align="left">35 (83)</td><td align="left">28 (80)</td><td align="left">39 (89)</td><td align="left">32 (89)</td><td></td></tr><tr><td align="left"><bold>Tumor of cardia</bold></td><td></td><td></td><td></td><td></td><td align="left">0.56</td></tr><tr><td align="left">Yes</td><td align="left">19 (45)</td><td align="left">14 (40)</td><td align="left">15 (34)</td><td align="left">12 (33)</td><td></td></tr><tr><td align="left">Others</td><td align="left">23 (55)</td><td align="left">21 (60)</td><td align="left">29 (66)</td><td align="left">24 (67)</td><td></td></tr><tr><td align="left"><bold>Metastatic site</bold></td><td></td><td></td><td></td><td></td><td align="left">0.92</td></tr><tr><td align="left">Liver</td><td align="left">7 (17)</td><td align="left">7 (20)</td><td align="left">9 (20)</td><td align="left">7 (20)</td><td></td></tr><tr><td align="left">Peritoneum</td><td align="left">13 (31)</td><td align="left">10 (29)</td><td align="left">14 (32)</td><td align="left">9 (25)</td><td></td></tr><tr><td align="left">Para aortic</td><td align="left">5 (12)</td><td align="left">4 (11)</td><td align="left">3 (7)</td><td align="left">3 (8)</td><td></td></tr><tr><td align="left">Multiple sites</td><td align="left">17 (40)</td><td align="left">14 (40)</td><td align="left">18 (41)</td><td align="left">17 (47)</td><td></td></tr><tr><td align="left"><bold>Primary disease</bold></td><td></td><td></td><td></td><td></td><td align="left">0.93</td></tr><tr><td align="left">Yes</td><td align="left">30 (71)</td><td align="left">24 (69)</td><td align="left">33 (75)</td><td align="left">25 (69)</td><td></td></tr><tr><td align="left">No (recurrent)</td><td align="left">12 (29)</td><td align="left">11 (31)</td><td align="left">11 (25)</td><td align="left">11 (31)</td><td></td></tr><tr><td align="left"><bold>Response to chemotherapy</bold></td><td></td><td></td><td></td><td></td><td align="left">0.69</td></tr><tr><td align="left">Responding (complete and partial)</td><td align="left">17 (40)</td><td align="left">13 (37)</td><td align="left">18 (41)</td><td align="left">15 (42)</td><td></td></tr><tr><td align="left">Not responding (stable or progressive disease)</td><td align="left">25 (60)</td><td align="left">22 (63)</td><td align="left">26 (59)</td><td align="left">21 (58)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>Epirubicin, cisplatin and 5-FU</p><p><sup>2 </sup>Docetaxel, cisplatin and 5-FU</p><p><sup>3 </sup>Those who completed the quality of life questionnaire</p><p><sup>4 </sup>P values derived from t-test or chi-square analyses for comparison between two groups of patients who completed the quality of life questionnaire</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Quality of life baseline scores as measured by the EORTC QLQ-C30 for each study arms</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>ECF group</bold></td><td align="left"><bold>TCF group</bold></td><td align="left"><bold>P</bold></td></tr></thead><tbody><tr><td></td><td align="left">Mean (SD)</td><td align="left">Mean (SD)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold>Functioning scores*</bold></td><td></td><td></td><td></td></tr><tr><td align="left">Physical functioning</td><td align="left">65.3 (13.4)</td><td align="left">66.1 (11.1)</td><td align="left">0.79</td></tr><tr><td align="left">Role functioning</td><td align="left">68.5 (15.5)</td><td align="left">68.0 (18.4)</td><td align="left">0.89</td></tr><tr><td align="left">Emotional functioning</td><td align="left">64.0 (12.1)</td><td align="left">56.6 (14.7)</td><td align="left">0.02</td></tr><tr><td align="left">Cognitive functioning</td><td align="left">85.7 (10.8)</td><td align="left">84.2 (14.3)</td><td align="left">0.61</td></tr><tr><td align="left">Social functioning</td><td align="left">68.1 (13.6)</td><td align="left">68.5 (13.1)</td><td align="left">0.89</td></tr><tr><td align="left">Global quality of life</td><td align="left">55.2 (17.4)</td><td align="left">45.1 (14.4)</td><td align="left">0.01</td></tr><tr><td align="left"><bold>Symptom scores**</bold></td><td></td><td></td><td></td></tr><tr><td align="left">Fatigue</td><td align="left">43.5 (14.8)</td><td align="left">49.6 (17.3)</td><td align="left">0.11</td></tr><tr><td align="left">Nausea and vomiting</td><td align="left">22.8 (19.8)</td><td align="left">33.8 (23.7)</td><td align="left">0.04</td></tr><tr><td align="left">Pain</td><td align="left">40.0 (16.7)</td><td align="left">47.1 (21.2)</td><td align="left">0.12</td></tr><tr><td align="left">Dyspnoea</td><td align="left">7.62 (16.3)</td><td align="left">12.0 (21.3)</td><td align="left">0.33</td></tr><tr><td align="left">Sleep difficulties</td><td align="left">31.4 (25.5)</td><td align="left">40.7 (21.2)</td><td align="left">0.09</td></tr><tr><td align="left">Appetite loss</td><td align="left">39.0 (22.1)</td><td align="left">46.3 (24.3)</td><td align="left">0.19</td></tr><tr><td align="left">Constipation</td><td align="left">14.3 (21.8)</td><td align="left">14.8 (26.9)</td><td align="left">0.93</td></tr><tr><td align="left">Diarrhoea</td><td align="left">3.81 (10.7)</td><td align="left">9.25 (18.8)</td><td align="left">0.14</td></tr><tr><td align="left">Financial difficulties</td><td align="left">52.4 (20.2)</td><td align="left">44.4 (21.1)</td><td align="left">0.11</td></tr></tbody></table><table-wrap-foot><p>* Higher scores show better functioning and global quality of life.</p><p>** Higher scores indicate greater symptoms.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Quality of life mean score changes before and after 3 cycles of chemotherapy (follow-up scores minus baseline scores) for each study arms</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>ECF group</bold></td><td></td><td align="left"><bold>TCF group</bold></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Functioning scores<sup>1</sup></bold></td><td align="left">Mean (SD) score changes</td><td align="left">P<sup>3</sup></td><td align="left">Mean (SD) score changes</td><td align="left">P<sup>3</sup></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Physical functioning</td><td align="left">4.1 (13.6)</td><td align="left">0.08</td><td align="left">2.3 (14.8)</td><td align="left">0.36</td></tr><tr><td align="left">Role functioning</td><td align="left">0.57 (14.3)</td><td align="left">0.81</td><td align="left">2.7 (18.9)</td><td align="left">0.38</td></tr><tr><td align="left">Emotional functioning</td><td align="left">-0.06 (8.3)</td><td align="left">0.96</td><td align="left">8.0 (15.4)</td><td align="left">0.004</td></tr><tr><td align="left">Cognitive functioning</td><td align="left">-2.5 (13.4)</td><td align="left">0.27</td><td align="left">-6.1 (17.0)</td><td align="left">0.04</td></tr><tr><td align="left">Social functioning</td><td align="left">-2.3 (14.6)</td><td align="left">0.36</td><td align="left">5.2 (14.1)</td><td align="left">0.03</td></tr><tr><td align="left">Global quality of life</td><td align="left">2.4 (14.5)</td><td align="left">0.34</td><td align="left">9.7 (16.8)</td><td align="left">0.001</td></tr><tr><td align="left"><bold>Symptom scores<sup>2</sup></bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Fatigue</td><td align="left">-0.99 (14.8)</td><td align="left">0.69</td><td align="left">-4.6 (14.1)</td><td align="left">0.05</td></tr><tr><td align="left">Nausea and vomiting</td><td align="left">-3.5 (19.6)</td><td align="left">0.29</td><td align="left">-1.4 (29.9)</td><td align="left">0.78</td></tr><tr><td align="left">Pain</td><td align="left">-6.3 (14.2)</td><td align="left">0.01</td><td align="left">-5.7 (15.1)</td><td align="left">0.03</td></tr><tr><td align="left">Dyspnoea</td><td align="left">-2.6 (14.9)</td><td align="left">0.31</td><td align="left">-0.92 (20.3)</td><td align="left">0.78</td></tr><tr><td align="left">Sleep difficulties</td><td align="left">-5.8 (23.5)</td><td align="left">0.15</td><td align="left">-11.3 (27.5)</td><td align="left">0.02</td></tr><tr><td align="left">Appetite loss</td><td align="left">-4.6 (19.8)</td><td align="left">0.17</td><td align="left">-5.4 (29.3)</td><td align="left">0.27</td></tr><tr><td align="left">Constipation</td><td align="left">-1.1 (29.4)</td><td align="left">0.83</td><td align="left">0.92 (36.9)</td><td align="left">0.88</td></tr><tr><td align="left">Diarrhoea</td><td align="left">9.8 (19.0)</td><td align="left">0.004</td><td align="left">0.32 (27.6)</td><td align="left">0.94</td></tr><tr><td align="left">Financial difficulties</td><td align="left">9.1 (23.6)</td><td align="left">0.03</td><td align="left">11.6 (19.3)</td><td align="left">0.001</td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>For functioning scores positive values show improvements and negative values indicate deteriorations.</p><p><sup>2 </sup>For symptom scores negative values show improvements and positive values indicate deteriorations.</p><p><sup>3 </sup>P values derived from the paired t-tests.</p><p>SD = Standard deviation</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Comparison of quality of life scores between two groups after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>ECF group</bold></td><td align="left"><bold>TCF group</bold></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Functioning scores<sup>1</sup></bold></td><td align="left">Mean (SD) score</td><td align="left">Mean (SD) score</td><td align="left">P<sup>3</sup></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Physical functioning</td><td align="left">69.4 (14.9)</td><td align="left">68.3 (19.1)</td><td align="left">0.81</td></tr><tr><td align="left">Role functioning</td><td align="left">69.1 (16.7)</td><td align="left">70.8 (21.2)</td><td align="left">0.71</td></tr><tr><td align="left">Emotional functioning</td><td align="left">63.9 (12.5)</td><td align="left">64.6 (13.5)</td><td align="left">0.82</td></tr><tr><td align="left">Cognitive functioning</td><td align="left">83. 2 (11.4)</td><td align="left">78.1 (13.1)</td><td align="left">0.08</td></tr><tr><td align="left">Social functioning</td><td align="left">65. 8(15.6)</td><td align="left">73.7 (15.5)</td><td align="left">0.03</td></tr><tr><td align="left">Global quality of life</td><td align="left">57.6 (15.1)</td><td align="left">54.8 (16.3)</td><td align="left">0.46</td></tr><tr><td align="left"><bold>Symptom scores<sup>2</sup></bold></td><td></td><td></td><td></td></tr><tr><td align="left">Fatigue</td><td align="left">42.5 (12.7)</td><td align="left">44.9 (16.7)</td><td align="left">0.48</td></tr><tr><td align="left">Nausea and vomiting</td><td align="left">19.3 (16.7)</td><td align="left">32.4 (26.1)</td><td align="left">0.01</td></tr><tr><td align="left">Pain</td><td align="left">32.8 (17.1)</td><td align="left">41.4 (22.6)</td><td align="left">0.08</td></tr><tr><td align="left">Dyspnoea</td><td align="left">7.6 (16.3)</td><td align="left">11.1 (21.1)</td><td align="left">0.13</td></tr><tr><td align="left">Sleep difficulties</td><td align="left">25.5 (21.4)</td><td align="left">29.4 (22.2)</td><td align="left">0.45</td></tr><tr><td align="left">Appetite loss</td><td align="left">34.4 (24.9)</td><td align="left">40.8 (27.7)</td><td align="left">0.31</td></tr><tr><td align="left">Constipation</td><td align="left">13.2 (21.2)</td><td align="left">15.7 (25.8)</td><td align="left">0.65</td></tr><tr><td align="left">Diarrhoea</td><td align="left">13.6 (19.9)</td><td align="left">9.5 (17.0)</td><td align="left">0.35</td></tr><tr><td align="left">Financial difficulties</td><td align="left">61.4 (25.7)</td><td align="left">56.0 (24.8)</td><td align="left">0.37</td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>Higher scores show better functioning and global quality of life.</p><p><sup>2 </sup>Higher scores indicate greater symptoms.</p><p><sup>3 </sup>P values derived from independent samples t-tests.</p><p>SD = Standard deviation</p></table-wrap-foot></table-wrap></sec></back></article>